| 11/8/2018 | CVIG | Moody's rates Allergan notes Baa3
|
| 11/24/2015 | CVIG | Fitch puts Allergan on positive watch
|
| 11/23/2015 | CVIG | Moody’s reviews Allergan, Actavis, Forest
|
| 5/12/2015 | BKCVIG | S&P lowers Allergan
|
| 3/17/2015 | BKCVIG | Fitch cuts Allergan, affirms Actavis
|
| 4/23/2014 | CVIG | Fitch puts Allergan on watch
|
| 4/23/2014 | CVIG | S&P: Allergan on watch
|
| 3/7/2013 | CVIG | Fitch rates Allergan notes A+
|
| 3/7/2013 | CVIG | S&P rates Allergan notes A+
|
| 3/7/2013 | CVIG | Moody's: Allergan notes A3
|
| 1/24/2013 | CVIG | Moody's: Allergan unchanged
|
| 1/23/2013 | CVIG | Fitch: Allergan unchanged
|
| 8/6/2012 | CVIGPF | Allergan files automatic shelf for debt securities, preferreds, stock
|
| 5/31/2012 | BKCVIG | S&P lifts health companies
|
| 3/13/2012 | CVIG | Fitch upgrades Allergan
|
| 3/16/2011 | CVIG | Fitch ups Allergan
|
| 3/16/2011 | CV | Market Commentary: RAIT Financial gains on debut; Illumina, USEC lag again; Allergan's notes trade at parity
|
| 3/14/2011 | CV | Market Commentary: USEC drops dollar neutral on Japan's nuclear crisis; Chesapeake up; Illumina, RAIT on tap
|
| 3/11/2011 | CV | Market Commentary: Convertibles market eyes new paper; week sees more than $2 billion of issuance; Cemex off
|
| 3/8/2011 | CV | Market Commentary: Allergan off on call news; Hutchinson drops; TiVo on tap; Cemex launches $1.2 billion deal
|
| 3/7/2011 | CVLM | Allergan calls $649.73 million 1.5% convertible senior notes due 2026
|
| 2/17/2011 | CV | Market Commentary: NetApp falls outright, flat on hedge; Allergan comes in slightly; KV Pharma extends gains
|
| 1/13/2011 | CV | Market Commentary: Dendreon to price $500 million convertibles; Allergan active amid possible short covering
|
| 11/1/2010 | CV | Market Commentary: Planned Stanley Black & Decker seen 3-4 points cheap; Developers Diversified up in gray
|
| 10/18/2010 | CV | Market Commentary: NII Holdings flat to lower on scuttled wireless agreement; EMC mixed; Cubist deal on tap
|
| 10/11/2010 | CV | Market Commentary: LDK adds as shares surge on raised view; Allergan steady; newish SL Green trades over par
|
| 9/7/2010 | CVIG | S&P rates Allergan notes A+
|
| 9/7/2010 | CVIG | Moody's rates Allergan notes A3
|
| 9/7/2010 | CVIG | Fitch rates Allergan notes A-
|
| 9/3/2010 | CV | Market Commentary: Convertibles quiet, ride stronger equity markets; SanDisk holds on to gains; Agco improves
|
| 9/1/2010 | CVIG | Moody's: Allergan unchanged
|
| 8/20/2010 | CV | Market Commentary: New SanDisk slips below par on debut; older SanDisk weakens; Intel active; volumes light
|
| 7/21/2010 | CVIG | S&P rates Allergan notes A+
|
| 4/27/2010 | CVIG | S&P lifts Allergan
|
| 3/30/2010 | CVIG | Fitch affirms Allergan
|
| 3/24/2010 | CV | Market Commentary: Cemex talk revised, deal upsized; new Kaiser higher, mostly quiet; MF Global up; Newmont off
|
| 3/5/2010 | CV | Market Commentary: Priceline trades to 101 on debut; Nektar extends gains; SandDisk retraces gains; AMD rises
|
| 8/21/2009 | CV | Market Commentary: Freeport higher on upbeat outlook; Mylan, Hologic, Allergan mixed; Alcoa, Newell unchanged
|
| 7/20/2009 | CV | Market Commentary: Human Genome surges on lupus trial; Lincare trades before earnings; CIT busy; Intel to price
|
| 3/31/2009 | CVIG | Fitch affirms Allergan
|
| 3/12/2009 | CV | Market Commentary: CV Therapeutics higher, Gilead slips on merger news; Johnson Controls convertibles move upward
|
| 3/5/2009 | CV | Market Commentary: Ford adds points on debt swap; financials weaker again, US Bancorp trades; BRE Properties lower
|
| 3/2/2009 | CVIG | Allergan files automatic shelf registration
|
| 12/18/2008 | CV | Market Commentary: Convertibles stronger: Mylan adds 0.5 point; strong bid on IG names; Allergan 1.5% notes up to par
|
| 8/1/2008 | CV | Market Commentary: Washington Mutual, Ambac Financial edge higher; General Growth strengthens; General Motors down
|
| 3/17/2008 | CVIG | Fitch affirms Allergan
|
| 2/8/2008 | CV | Market Commentary: Qimonda slips on opening day; Chiquita moves higher; Peabody ends week higher; Allergan falls on Botox warning
|
| 7/19/2007 | CV | Market Commentary: Newmont, CVRD see gold rush; Allergan up but no one knows why; SunPower launches early
|
| 5/7/2007 | CV | Market Commentary: Armor climbs on BAE buyout; Yahoo! fades with merger hopes; Gold Reserve, Chemed launch deals
|
| 3/22/2007 | CV | Fitch affirms Allergan
|
| 6/12/2006 | CV | Market Commentary: Symantec reoffers, prices deal at cheap end of talk; NPS unmoved by restructuring; Comverse slides
|
| 5/5/2006 | CV | Market Commentary: Safenet gains on earnings, stock buyback; Scottish Re widens after poor quarter; Finisar flat after rally
|
| 4/12/2006 | BTCV | Allergan to redeem zero-coupon convertibles due 2022
|
| 4/10/2006 | CV | Market Commentary: Red Hat gains 8 points outright on acquisition; Oscient keeps sliding; Rentech deal sees poor interest
|
| 4/7/2006 | CV | Market Commentary: Safenet convertibles gain against stock crash; Allergan falls on debut; Rentech sets talk on new deal
|
| 4/7/2006 | BTCV | New Issue: Allergan prices $700 million of 20-year convertibles at 1.5%, up 20%, greenshoe exercised
|
| 4/6/2006 | CV | Allergan prices $700 million convertibles to yield 1.5%, up 20%
|
| 4/6/2006 | CV | Market Commentary: Allergan new deal stumbles in the gray; Annaly offering seen as hedge play; Cell Therapeutics plans deal
|
| 4/5/2006 | BTCV | Allergan to redeem zero-coupon convertibles due 2022
|
| 4/5/2006 | CV | Market Commentary: Conexant gains on report; ON Semiconductor up despite downgrade; Ciena struggles off the blocks
|
| 4/5/2006 | BTCV | Allergan to offer $700 million of 20-year convertibles talked at 1%-1.5%, up 20% to 25%
|
| 4/4/2006 | BTCV | Moody's rates Allergan notes, convertibles A3
|
| 3/29/2006 | BTCV | Fitch downgrades Allergan
|
| 3/28/2006 | BTCV | S&P affirms Allergan
|
| 11/15/2005 | BTCV | Moody's may cut Allergan long-term ratings
|
| 11/15/2005 | BTCV | S&P places Allergan on negative watch
|
| 11/15/2005 | BTCV | Fitch places Allergan on negative watch
|
| 11/15/2005 | CV | Market Commentary: Ford, GM, oil and gas, airlines down; EDO shows up in the gray; Pantry, C&D, E*Trade deals ahead
|
| 4/15/2005 | CV | Market Commentary: GM, Ford selling accelerates; El Paso, Calpine, NRG plunge; Ivax, Teva lose; Lucent, Tyco unwound
|
| 2/9/2005 | CV | Market Commentary: Protein Design Labs sweetened, sinks; Huntsman hotly pursued; Allergan, Sepracor off, Saks up
|
| 7/13/2004 | CV | S&P: Allergan unaffected
|
| 10/15/2003 | CV | S&P ups Teva to BBB
|
| 7/22/2003 | CV | Market Commentary: Buyers tiptoeing back into market as premiums contract; Wells Fargo rekindles dividend fears
|
| 7/11/2003 | CV | Lehman finds options market signaling several converts have high dividend risk
|
| 5/7/2003 | CV | Allergan plans to redeem remaining convertibles due 2020 in November
|
| 4/28/2003 | CV | S&P ups AmeriSource-Bergen
|
| 12/17/2002 | CV | Allergan says $588 million principal LYONs tendered
|
| 11/18/2002 | CV | Allergan starts tender offer of 0% LYONs due 2020
|
| 11/18/2002 | CV | Market Commentary: Trickle of new issues providing hope for eager buyers
|
| 11/7/2002 | CV | Market Commentary: Faithful players trudge on with buying strategy amidst retreat
|
| 11/5/2002 | CV | Market Commentary: New deals improve trading flow as market awaits Fed
|
| 11/1/2002 | CV | Moody's cuts Nortel
|
| 11/1/2002 | CV | Market Commentary: Allergan new 0% convertible takes center stage and trades higher on quiet Friday
|
| 10/31/2002 | CV | New Issue: Allergan $450 million proceeds convertible yields 1.25%, up 25.45%
|
| 10/31/2002 | CV | Market Commentary: Firm tone on rising confidence; Allergan prices $450 million, Lucent, EDS active
|
| 10/24/2002 | CV | S&P keeps AOL Time Warner on watch
|
| 9/23/2002 | CV | Fitch lowers Teco Energy
|
| 6/21/2002 | CV | Deutsche: Allergan seen at discount due to uncertainty with Advanced Medical spin-off
|
| 4/12/2002 | CV | Market Commentary: Quiet session ends quiet week on higher note; Cendant lower on accounting questions
|
| 1/22/2002 | CV | Moody's downgrades Kmart
|
